Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528567 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL260631 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178698 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401258 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29359997 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29423590 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401604 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119708 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL18148920 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119709 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250282820-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | PEPTIDREAM INC (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4501941-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | PeptiDream Inc. (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | PEPTIAID INC (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4317174-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | Peptiaid Inc (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230364255-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-11-16 | — | — | US | disclosed |
| US-20230220005-A1 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | TOKYO WOMEN'S MEDICAL UNIVERSITY (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230220005-A1 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | TOKYO WOMEN'S MEDICAL UNIVERSITY (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-6900213-B2 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1351941-B1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA, LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-5981500-A | Antiparasitic agents related to the milbemycins and avermectins | PFIZER INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0677054-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015944-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885MDM2 1169/4885MDM4 2010/4885 |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | FSHR, GNRHR, LHCGR | KMT2A 512/4885MDM2 2901/4885MDM4 4744/4885 |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | NGLY1, VIP, HM13 | KMT2A 2534/4885MDM2 3700/4885MDM4 973/4885 |
| US-20250282820-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | NTRK2, BDNF, NPY1R | KMT2A 1556/4885MDM2 3088/4885MDM4 4384/4885 |
| US-20230220005-A1 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | S100A8, S100A11, S100A4 | KMT2A 3890/4885MDM2 733/4885MDM4 939/4885 |
| US-20230364255-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | TGM2, TGM1, TGM6 | KMT2A 995/4885MDM2 1020/4885MDM4 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.